Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Moodys
Baxter
QuintilesIMS
Colorcon
Accenture
Fuji
UBS
Chubb

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Empagliflozin; Metformin Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT01001962 Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics Not yet recruiting Aristotle University Of Thessaloniki Phase 4 Objectives: Primary 1. Primary prevention of new onset of hypertension Secondary 1. Reduction of 24h BP in type II diabetics with prehypertension 2. Reduction of non dipping status, day and nighttime BP, morning BP surge in subjects receiving EMPAGLIFLOZIN 3. Reduction in the total cardiovascular risk 4. 3 years morbidity and mortality rates 5. Arterial de-stiffening, reduction in central aortic blood pressure in subjects receiving EMPAGLIFLOZIN
NCT01159600 Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.
NCT01159600 Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes Completed Boehringer Ingelheim Phase 3 The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.
NCT01167881 Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic control.
NCT01167881 Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes Completed Boehringer Ingelheim Phase 3 This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic control.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Empagliflozin; Metformin Hydrochloride

Condition Name

Condition Name for Empagliflozin; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 14
Healthy 13
Type 2 Diabetes Mellitus 5
Type2 Diabetes Mellitus 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Empagliflozin; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus 26
Diabetes Mellitus, Type 2 26
Fatty Liver 2
Hypertension 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Empagliflozin; Metformin Hydrochloride

Trials by Country

Trials by Country for Empagliflozin; Metformin Hydrochloride
Location Trials
United States 184
Canada 44
Germany 18
Australia 12
Spain 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Empagliflozin; Metformin Hydrochloride
Location Trials
Texas 13
Florida 11
Georgia 10
California 9
North Carolina 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Empagliflozin; Metformin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Empagliflozin; Metformin Hydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 12
Phase 2/Phase 3 1
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Empagliflozin; Metformin Hydrochloride
Clinical Trial Phase Trials
Completed 20
Not yet recruiting 10
Recruiting 9
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Empagliflozin; Metformin Hydrochloride

Sponsor Name

Sponsor Name for Empagliflozin; Metformin Hydrochloride
Sponsor Trials
Boehringer Ingelheim 25
Eli Lilly and Company 17
Medanta, The Medicity, India 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Empagliflozin; Metformin Hydrochloride
Sponsor Trials
Industry 51
Other 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Cantor Fitzgerald
Daiichi Sankyo
Mallinckrodt
Deloitte
Medtronic
Argus Health
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.